Heron Therapeutics (HRTX) Cash & Current Investments (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Cash & Current Investments data on file, last reported at $44.8 million in Q1 2026.

• Quarterly Cash & Current Investments rose 25.76% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.8 million (up 25.76% YoY) and the FY2025 annual result came in at $46.6 million, down 21.34% from the prior year.
• Cash & Current Investments eased to $44.8 million in Q1 2026, from $46.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $121.7 million in Q3 2022 to a low of $26.7 million in Q2 2025.
• A 5-year average of $56.6 million and a median of $56.6 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 67.58% — and 2024, when it surged 104.75%.
• Tracing HRTX's Cash & Current Investments over 5 years: stood at $71.0 million in 2022, then fell by 19.66% to $57.0 million in 2023, then increased by 3.95% to $59.3 million in 2024, then retreated by 21.34% to $46.6 million in 2025, then fell by 3.96% to $44.8 million in 2026.
• The last three Cash & Current Investments figures came in at $44.8 million (Q1 2026), $46.6 million (Q4 2025), and $29.3 million (Q3 2025), per Business Quant data.